Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 1;137(7):1749-57.
doi: 10.1002/ijc.29538. Epub 2015 Apr 21.

Prevalence of incidental prostate cancer: A systematic review of autopsy studies

Katy J L Bell  1   2 , Chris Del Mar  1 , Gordon Wright  3 , James Dickinson  4   5 , Paul Glasziou  1
Affiliations

Prevalence of incidental prostate cancer: A systematic review of autopsy studies

Katy J L Bell et al. Int J Cancer. .

Abstract

Prostate cancer screening may detect nonprogressive cancers, leading to overdiagnosis and overtreatment. The potential for overdiagnosis can be assessed from the reservoir of prostate cancer in autopsy studies that report incidental prostate cancer rates in men who died of other causes. We aimed to estimate the age-specific incidental cancer prevalence from all published autopsy studies. We identified eligible studies by searches of Medline and Embase, forward and backward citation searches and contacting authors. We screened the titles and abstracts of all articles; checked the full-text articles for eligibility and extracted clinical and pathology data using standardized forms. We extracted mean cancer prevalence, age-specific cancer prevalence and validity measures and then pooled data from all studies using logistic regression models with random effects. The 29 studies included in the review dated from 1948 to 2013. Incidental cancer was detected in all populations, with no obvious time trends in prevalence. Prostate cancer prevalence increased with each decade of age, OR = 1.7 (1.6-1.8), and was higher in studies that used the Gleason score, OR = 2.0 (1.1-3.7). No other factors were significantly predictive. The estimated mean cancer prevalence increased in a nonlinear fashion from 5% (95% CI: 3-8%) at age <30 years to 59% (95% CI: 48-71%) by age >79 years. There was substantial variation between populations in estimated cancer prevalence. There is a substantial reservoir of incidental prostate cancer which increases with age. The high risk of overdiagnosis limits the usefulness of prostate cancer screening.

Keywords: autopsy; early detection of cancer; mass screening; prostatic neoplasms.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Search and selection of primary studies for the meta-analysis.
Figure 2
Figure 2
Prevalence of incidental prostate cancer in studies by year of publication.
Figure 3
Figure 3
Decade-specific prevalence of: (i) incidental prostate cancer from studies and (ii) mean prevalence from models before and after adjustment for use of Gleason score 294 × 188 mm (100 × 100 DPI).
See this image and copyright information in PMC

Comment in

References

    1. U.S. Cancer Statistics Working Group. 2014. United States Cancer Statistics: 1999–2011. Incidence and mortality web-based report. Atlanta, GA: Department of Health and Human Services,
    1. OECD/European Union. Mortality from cancer. Health at a glance: Europe 2014. Paris: OECD Publishing; 2014.
    1. Mariotto AB, Etzioni R, Krapcho M, et al. Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the national health interview survey. Cancer. 2007;109:1877–86. - PubMed
    1. Jonsson H, Holmstrom B, Duffy SW, et al. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden. Int J Cancer. 2011;129:1881–8. - PubMed
    1. Drummond FJ, Carsin AE, Sharp L, et al. Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines. Irish J Med Sci. 2010;179:43–9. - PubMed

Publication types